CRISPR Therapeutics AG (CRSP) Operating Leases (2019 - 2025)
CRISPR Therapeutics AG (CRSP) has disclosed Operating Leases for 7 consecutive years, with $188.2 million as the latest value for Q4 2025.
- Quarterly Operating Leases fell 8.84% to $188.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $188.2 million through Dec 2025, down 8.84% year-over-year, with the annual reading at $188.2 million for FY2025, 8.84% down from the prior year.
- Operating Leases hit $188.2 million in Q4 2025 for CRISPR Therapeutics AG, down from $192.8 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $234.2 million in Q2 2022 to a low of $49.4 million in Q1 2021.
- Historically, Operating Leases has averaged $204.4 million across 5 years, with a median of $213.9 million in 2021.
- Biggest five-year swings in Operating Leases: skyrocketed 399.7% in 2021 and later fell 8.84% in 2025.
- Year by year, Operating Leases stood at $212.9 million in 2021, then grew by 7.19% to $228.2 million in 2022, then fell by 2.27% to $223.0 million in 2023, then fell by 7.44% to $206.4 million in 2024, then dropped by 8.84% to $188.2 million in 2025.
- Business Quant data shows Operating Leases for CRSP at $188.2 million in Q4 2025, $192.8 million in Q3 2025, and $197.4 million in Q2 2025.